• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Know Labs Inc.

    4/25/25 4:16:10 PM ET
    $KNW
    Industrial Machinery/Components
    Industrials
    Get the next $KNW alert in real time by email
    S-8 1 knwn_s8.htm FORM S-8 knwn_s8.htm

    As filed with the Securities and Exchange Commission on April 25, 2025

     

    Registration No. 333- ___

      

    UNITED STATES 

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

    KNOW LABS, INC.

    (Exact name of Registrant as specified in its charter)

     

    Nevada

     

    90-0273142

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification Number)

     

    619 Western Avenue, Suite 610

    Seattle, Washington 98104

    (Address, including zip code, of Registrant’s principal executive office)

     

    Know Labs, Inc. 2021 Equity Incentive Plan

    (Full title of the plan)

     

    Ronald P. Erickson, Chairman of the Board

    Know Labs, Inc.

    619 Western Avenue, Suite 610

    Seattle, WA 98104

    206-903-1351

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

     

    Copies to: 

    Jessica M. Lockett, Esq.

    Corporate Securities Legal, LLP

    650 Town Center Dr., Suite 680

    Costa Mesa, CA 92626

    (949) 752-1100

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer

    ☐

    Accelerated filer

    ☐

    Non-accelerated filer

    ☒

    Smaller reporting company

    ☒

     

     

    Emerging growth company

    ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     

     

    EXPLANATORY NOTE

     

    This Registration Statement is filed by Know Labs, Inc. (the “Registrant”) for the purpose of registering an aggregate 550,000  additional shares of the Registrant’s common stock, par value $0.001 per share (the “Common Stock”) under the Know Labs, Inc.  2021 Equity Incentive Plan (the “Plan”) following the amendment to the Plan that was approved by the Registrant’s stockholders at its special meeting on October 25, 2024 (“Special Meeting”), as adjusted for the Reverse Stock Split (as defined below). The aggregate 550,000 shares represents:

     

     

    (i)

    450,000 share increase in the Plan, as adjusted for the Reverse Stock Split, as approved at the October 25, 2024 meeting of stockholders;

     

    (ii)

    50,000 share increase, as adjusted for the Reverse Stock Split, which were automatically added to the Plan on January 1, 2022 pursuant to the “evergreen” provision of the Plan; and

     

    (iii)

    50,000 share increase, as adjusted for the Reverse Stock Split, which were automatically added to the Plan on January 1, 2025 pursuant to the “evergreen” provision of the Plan.

     

    The Registrant initially registered, as adjusted for the Reverse Stock Split, 500,000 shares under the Plan and 366,253 shares of Common Stock reserved for issuance under the 2011 Stock Incentive Plan, as amended (the “2011 Plan”), respectively, on Form S-8 filed with the Securities and Exchange Commission (the "Commission") on December 10, 2021 (File No. 333-261597). On October 25, 2024, at the Special Meeting of stockholders, an amendment to the Plan was approved, increasing the aggregate number of shares of Common Stock available for issuance under the Plan to 1,000,000 shares, as adjusted for the Reverse Stock Split (as defined below), plus 189,821 shares reserved for issuance under the 2011 Plan.

     

    The “evergreen” provisions of the Plan provide that the maximum number of shares of Common Stock authorized under the Plan shall be increased on the first day of each calendar year beginning January 1, 2022 and ending on and including January 1, 2030 in an amount equal to the least of (i) 50,000 Shares, as adjusted for the Reverse Stock Split, (ii) four percent (4%) of the outstanding Shares on the last day of the immediately preceding Fiscal Year or (iii) such number of Shares determined by the Board; provided, that such determination under clause (iii) will be made no later than the last day of the immediately preceding Fiscal Year.

     

    On February 18, 2025, the Registrant announced a one-for-40 reverse stock split of the Registrant’s authorized and issued and outstanding shares of Common Stock (the “Reverse Stock Split”), which became effective on February 19, 2025. As a result of the Reverse Stock Split, every 40 shares of Common Stock issued and outstanding were converted into one share of Common Stock. The number of shares to be awarded under the Plan and the number of additional shares available pursuant to the “evergreen” provisions are also being appropriately adjusted as a result of the Reverse Stock Split.

     

    Pursuant to General Instruction E of Form S-8, the contents of Registration Statement on Form S-8 (File No. 333-261597), filed by the Registrant with the Commission on December 10, 2021, are incorporated into this Registration Statement by reference to the extent not modified or superseded hereby or by any subsequently filed document, which is incorporated by reference herein or therein.

     

     
    2

     

     

    PART I

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

     

    In accordance with the rules and regulations of the Commission, the information called for in Part I of Form S-8 is not being filed with or included in this Registration Statement or in a prospectus or prospectus supplement pursuant to Rule 424 of the Securities Act.

     

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 8. Exhibits.

     

    A list of exhibits included as part of this Registration Statement is set forth in the Exhibit Index to this Registration Statement and is incorporated herein by reference.

     

    Exhibit

    Number

     

    Exhibit Description

     

     

     

     

     

     

    Filed herewith

     

    Incorporated

    by Reference

    herein from

    Form or Schedule

     

    Filing Date

    3.1

     

    Restatement of the Articles of Incorporation, dated August 11, 2023

     

     

     

    Form 8-K

     

    August 14, 2023

    3.2

     

    Second Amended and Restated Bylaws, dated October 15, 2021

     

     

     

    Form 8-K

     

    December 7, 2021

    4.1

     

    2021 Know Labs, Inc. Equity Incentive Plan, as amended (to reflect Reverse Stock Split)

     

    X

     

     

     

     

    5.1

     

    Opinion of Corporate Securities Legal, LLP, filed herewith

     

    X

     

     

     

     

    23.1

     

    Consent of BPM LLP, independent registered public accounting firm

     

    X

     

     

     

     

    23.2

     

    Consent of Corporate Securities Legal, LLP (included in Exhibit 5.1)

     

    X

     

     

     

     

    24.1

     

    Power of Attorney (included on signature page hereto)

     

    X

     

     

     

     

    107

     

    Filing Fee Table

     

    X

     

     

     

     

     

     
    3

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of Seattle, Washington, on April 25, 2025.

     

     

    Know Labs, Inc.

     

     

     

     

    Date: April 25, 2025

    By:

    /s/ Ronald P. Erickson

     

     

     

    Ronald P. Erickson

     

     

     

    Chief Executive Officer, and

    Chairman of the Board of Directors

    (Principal Executive Officer)

     

     

    POWER OF ATTORNEY

     

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Ronald P. Erickson and Peter J. Conley and each or any one of them, their true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for each of the undersigned in his or her name, place and stead, in any and all capacities, to sign any and all amendments to this Registration Statement on Form S-8, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the U.S. Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as the undersigned might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their substitutes or substitute, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities indicated:

     

    Signature

     

    Title

     

    Date

     

     

     

     

     

    /s/ Ronald P. Erickson

     

    Chief Executive Officer, and Director

     

    April 25, 2025

    Ronald P. Erickson

     

    (Principal Executive Officer)

     

     

     

     

     

     

     

    /s/ Peter J. Conley

     

    Chief Financial Officer

     

    April 25, 2025

    Peter J. Conley

     

    (Principal Accounting Officer and

    Principal Financial Officer)

     

     

     

     

     

     

     

    /s/ William A. Owens

     

    Director

     

    April 25, 2025

    William A. Owens

     

     

     

     

     

     

     

     

     

    /s/ Jon Pepper

     

    Director

     

    April 25, 2025

    Jon Pepper

     

     

     

     

     

     

     

     

     

    /s/ Ichiro Takesako

     

    Director

     

    April 25, 2025

    Ichiro Takesako

     

     

     

     

     

     

     

     

     

    /s/ John Cronin

     

    Director

     

    April 25, 2025

    John Cronin

     

     

     

     

     

     

     

     

     

    /s/ Larry K, Ellingson

     

    Director

     

    April 25, 2025

    Larry K. Ellingson

     

     

     

     

     

     
    4

     

    Get the next $KNW alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $KNW

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $KNW
    Financials

    Live finance-specific insights

    See more
    • Know Labs, Inc. Reports Third Quarter FY2023 Results

      Know Labs, Inc. (NYSE:KNW), an emerging developer of non-invasive medical diagnostic technology, today reported financial results for the third quarter ended June 30, 2023. Financial Highlights: Know Labs reported a net loss of $3.59 million dollars in the third quarter of 2023, compared to a net loss of $3.03 million dollars in the year-ago period, which translates to Earnings Per Share of a loss of $0.07, unchanged from the year ago period of a loss of $0.07 before preferred stock dividends. Recorded a non-cash charge to earnings of $4.96 million related to the fair market value of dividends on the Company's Series C and D preferred stock, that were either paid or accrued in share

      8/14/23 4:15:00 PM ET
      $KNW
      Industrial Machinery/Components
      Industrials
    • Know Labs, Inc. Reports Second Quarter FY2023 Results

      Know Labs, Inc. (NYSE:KNW), an emerging developer of non-invasive medical diagnostic technology, today reported financial results for the second quarter ended March 31, 2023. Financial Highlights: Know Labs reported a net loss of $4.93 million dollars in the second quarter of 2023, compared to a net loss of $6.14 million dollars in the year-ago period, which translates to Earnings Per Share of a loss of $0.10, an improvement over the year ago period of a loss of $0.16. Research and development expense for the second quarter was $2.56 million dollars as compared to $1.25 million dollars in 2022. The increase in R&D expense was related to staff increases in engineering, third party te

      5/15/23 4:05:00 PM ET
      $KNW
      Industrial Machinery/Components
      Industrials
    • Know Labs, Inc. Reports First Quarter 2023 Results

      Know Labs, Inc. (NYSE:KNW), an emerging developer of non-invasive medical diagnostic technology, today reported financial results for the first quarter ended December 31, 2022. Financial Highlights: Know Labs reported a net loss of $3.82 million in the first quarter of 2023, compared to a net loss of $5.36 million in the first quarter of 2022, which translates to Earnings Per Share of a loss of $0.08 versus a loss of $0.15 in the year ago period. Research and development expense for the first quarter ended December 31, 2022, was $1.74 million as compared to $886,000 in the same year ago period. The increase in R&D expense was related to staff increases in engineering, third party techn

      2/14/23 4:00:00 PM ET
      $KNW
      Industrial Machinery/Components
      Industrials

    $KNW
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Know Labs Inc. (Amendment)

      SC 13D/A - KNOW LABS, INC. (0001074828) (Subject)

      6/3/24 2:11:39 PM ET
      $KNW
      Industrial Machinery/Components
      Industrials
    • SEC Form SC 13D filed by Know Labs Inc.

      SC 13D - KNOW LABS, INC. (0001074828) (Subject)

      10/25/23 7:27:11 PM ET
      $KNW
      Industrial Machinery/Components
      Industrials
    • SEC Form SC 13D/A filed by Know Labs Inc. (Amendment)

      SC 13D/A - KNOW LABS, INC. (0001074828) (Subject)

      10/19/23 6:32:18 AM ET
      $KNW
      Industrial Machinery/Components
      Industrials

    $KNW
    Leadership Updates

    Live Leadership Updates

    See more
    • Know Labs Appoints Chris Somogyi as President, International

      Somogyi to lead Know Labs' "Skunkworks" Program and drive global revenues. Know Labs, Inc. (NYSE:KNW), an emerging leader in non-invasive medical diagnostic technology, today announced the appointment of Chris Somogyi as President, International. With over 40 years of experience in commercializing innovation across related industries, Somogyi brings a wealth of expertise to lead the Company's "Skunkworks" Program and global patent licensing efforts. In his role, Somogyi will focus on identifying new applications of Know Labs' extensive intellectual property (IP) portfolio consisting of over 300 patents issued, pending and in-process and covering more than 100 medical and non-medical app

      5/16/24 9:00:00 AM ET
      $KNW
      Industrial Machinery/Components
      Industrials
    • Know Labs Expands Medical and Scientific Advisory Board

      New Members Bring Extensive Clinical Diabetes Management and FDA Expertise Know Labs, Inc. (NYSE:KNW), an emerging developer of non-invasive medical diagnostic technology, today announced the appointment of four new members to the Company's Medical and Scientific Advisory Board. The new additions to the Advisory Board are Jeff Hitchcock, Karmeen Kulkarni, Dr. Meng Tan and Dr. Satish Garg. They bring to the board extensive experience in clinical diabetes management, including the advancement of new technologies and innovation in medical diagnostics. The Medical and Scientific Advisory Board is chaired by Know Labs' Chief Medical Officer, Dr. James H. "Andy" Anderson. The Advisory Board p

      12/14/23 9:00:00 AM ET
      $KNW
      Industrial Machinery/Components
      Industrials
    • Know Labs Expands Board of Directors

      Appoints Three New Directors with Deep Sector Expertise Know Labs, Inc. (NYSE:KNW), an emerging developer of non-invasive medical diagnostic technology, today announced the appointment of three new members to the Company's Board of Directors. These appointments increase the number of Directors to seven. Each new Director brings to the board extensive sector-relevant experience with deep knowledge of the science and the marketplace that is the focus of Know Labs. The new appointees are John Cronin, Larry Ellingson and Tim Londergan. John Cronin is the founder and CEO of ipCapital Group, Inc., a leading global advisory company on intellectual property strategy and monetization. Cronin beg

      11/8/23 9:00:00 AM ET
      $KNW
      Industrial Machinery/Components
      Industrials

    $KNW
    SEC Filings

    See more

    $KNW
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $KNW
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Know Labs Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - KNOW LABS, INC. (0001074828) (Filer)

      6/6/25 9:00:35 AM ET
      $KNW
      Industrial Machinery/Components
      Industrials
    • Know Labs Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Unregistered Sales of Equity Securities, Material Modification to Rights of Security Holders, Financial Statements and Exhibits

      8-K - KNOW LABS, INC. (0001074828) (Filer)

      6/4/25 5:07:06 PM ET
      $KNW
      Industrial Machinery/Components
      Industrials
    • SEC Form 10-Q filed by Know Labs Inc.

      10-Q - KNOW LABS, INC. (0001074828) (Filer)

      5/14/25 4:24:08 PM ET
      $KNW
      Industrial Machinery/Components
      Industrials
    • SEC Form 4 filed by CEO Erickson Ronald P

      4 - KNOW LABS, INC. (0001074828) (Issuer)

      6/4/25 4:15:21 PM ET
      $KNW
      Industrial Machinery/Components
      Industrials
    • Director Takesako Ichiro John Paul was granted 25,000 shares, increasing direct ownership by 645% to 28,875 units (SEC Form 4)

      4 - KNOW LABS, INC. (0001074828) (Issuer)

      5/7/25 4:16:32 PM ET
      $KNW
      Industrial Machinery/Components
      Industrials
    • Director Ellingson Larry K was granted 25,000 shares, increasing direct ownership by 6,188% to 25,404 units (SEC Form 4)

      4 - KNOW LABS, INC. (0001074828) (Issuer)

      5/7/25 4:16:34 PM ET
      $KNW
      Industrial Machinery/Components
      Industrials
    • Greg Kidd to Acquire Controlling Interest in Know Labs and Introduce Bitcoin Treasury Strategy

      Know Labs, Inc. (NYSE American: KNW ("Know Labs" or the "Company"), a technology innovator specializing in non-invasive health monitoring solutions, today announced that it has entered into an agreement with Goldeneye 1995 LLC ("Buyer"), an affiliate of fintech investor, entrepreneur, and former Ripple Chief Risk Officer, Greg Kidd, to acquire a controlling interest in the Company. Upon the closing of the transaction, Mr. Kidd will become Chief Executive Officer and Chairman of the Board of Directors of the Company. Under the terms of the agreement, the Buyer will acquire that number of shares of the Company's common stock obtained by dividing (i) the sum of 1,000 Bitcoin and a cash sum t

      6/6/25 9:00:00 AM ET
      $KNW
      Industrial Machinery/Components
      Industrials
    • Know Labs Sensor Non-Invasively Identifies pH Levels in Real Time

      Significant Applications in Health Care, Food Quality and Safety and More Know Labs, Inc. (NYSE:KNW) is pleased to announce that it has completed extensive research in its laboratory utilizing its patented Radio Frequency Dielectric Spectroscopy (RFDS) sensor technology to identify changes in pH levels in real time. The research has been submitted for peer reviewed publication. The research is available for review today here on the Company's website at www.knowlabs.co. An abstract of the paper states, "We describe an experiment in which we employ a radio frequency sensor to measure pH changes in a liquid solution. The experiment is novel in a few ways. First, the sensor does not have cont

      3/19/25 9:00:00 AM ET
      $KNW
      Industrial Machinery/Components
      Industrials
    • Know Labs to Attend the 18th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD)

      The company to meet with potential strategic partners to discuss collaborating on advancing clinical research of its non-invasive blood glucose monitor Know Labs, Inc. (NYSE:KNW), an emerging developer of non-invasive medical diagnostic technology with its Radio Frequency Dialectic Spectroscopy (RFDS) platform, today announced the company will be attending The 18th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) Technology Fair in Amsterdam, Netherlands on March 19-22, 2025. The Company will share updates on the development of its non-invasive blood glucose monitor, since last year's conference, and discuss opportunities for collaboration and partnership

      3/18/25 9:00:00 AM ET
      $KNW
      Industrial Machinery/Components
      Industrials